Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level

被引：0
|
作者：
N. M. Atallah
M. Alsaleem
M. S. Toss
N. P. Mongan
E. Rakha
机构：
[1] the University of Nottingham and Nottingham University Hospitals NHS Trust,Division of Cancer and Stem Cells, School of Medicine
[2] Menoufia University,Department of Pathology, Faculty of Medicine
[3] Qassim University,Unit of Scientific Research, Applied College
[4] Sheffield Teaching Hospitals NHS Foundation Trust,Histopathology Department, Royal Hallamshire Hospital
[5] University of Nottingham,School of Veterinary Medicine and Sciences
[6] Weill Cornell Medicine,Department of Pharmacology
来源：
British Journal of Cancer | 2023年 / 129卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1692 / 1705
页数：13
相关论文
共 50 条
  • [41] Handling of anti-HER2 antibodies, trastuzumab and pertuzumab, in patients with HER2-positive breast cancer
    Araki, Kazuhiro
    Ito, Yoshinori
    ANNALS OF ONCOLOGY, 2015, 26 : 48 - 48
  • [42] Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism
    Schoellhammer, Hans F.
    Hsu, Felicia
    Vito, Courtney
    Chu, Peiguo
    Park, Jinha
    Waisman, James
    Kim, Joseph
    BMC CANCER, 2014, 14
  • [43] Anti-HER2 antibody therapy using gene-transduced adipocytes for HER2-positive breast cancer
    Masuda, Takahito
    Fujimoto, Hiroshi
    Teranaka, Ryotaro
    Kuroda, Masayuki
    Aoyagi, Yasuyuki
    Nagashima, Takeshi
    Sangai, Takafumi
    Takada, Mamoru
    Nakagawa, Ayako
    Kubota, Yoshitaka
    Yokote, Koutaro
    Ohtsuka, Masayuki
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (03) : 625 - 634
  • [44] Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer
    Yu, Anthony F.
    Singh, Jasmeet C.
    Wang, Rui
    Liu, Jennifer E.
    Eaton, Anne
    Oeffinger, Kevin C.
    Steingart, Richard M.
    Hudis, Clifford A.
    Dang, Chau T.
    ONCOLOGIST, 2017, 22 (06): : 642 - 647
  • [45] Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
    Scaltriti, Maurizio
    Rojo, Federico
    Ocana, Alberto
    Anido, Judit
    Guzman, Marta
    Cortes, Javier
    Di Cosimo, Serena
    Matias-Guiu, Xavier
    Ramon y Cajal, Santiago
    Arribas, Joaquin
    Baselga, Jose
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (08) : 628 - 638
  • [46] HER2 quantification by mass spectrometry compared to IHC or ISH in predicting clinical benefit from anti-HER2 therapy in HER2-positive breast cancer (BC)
    Nuciforo, Paolo
    Aura, Claudia
    Thyparambil, Sheeno P.
    Vilaro, Marta
    Garrido-Castro, Ana C.
    Peg, Vicente
    Jimenez, Jose
    Hoos, William Arthur
    Burrows, Jon
    Hembrough, Todd A.
    Perez-Garcia, Jose Manuel
    Cortes, Javier
    Scaltriti, Maurizio
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [47] Her2 positive subtype and breast cancer brain metastasis: any effect of anti-Her2 targeted therapy?
    Kadri Altundag
    Journal of Neuro-Oncology, 2017, 135 : 639 - 639
  • [48] Molecular Assessment of HER2 to Identify Signatures Associated with Therapy Response in HER2-Positive Breast Cancer
    Maddox, Adam L.
    Brehove, Matthew S.
    Eliato, Kiarash R.
    Saftics, Andras
    Romano, Eugenia
    Press, Michael F.
    Mortimer, Joanne
    Jones, Veronica
    Schmolze, Daniel
    Seewaldt, Victoria L.
    Jovanovic-Talisman, Tijana
    CANCERS, 2022, 14 (11)
  • [49] Her2 positive subtype and breast cancer brain metastasis: any effect of anti-Her2 targeted therapy?
    Altundag, Kadri
    JOURNAL OF NEURO-ONCOLOGY, 2017, 135 (03) : 639 - 639
  • [50] ESAM reduces anti-HER2 therapy sensitivity by activating mTOR pathway in HER2 positive breast cancer
    Wu, Jiong
    Zhou, Xujie
    Chi, Yayun
    Xue, Jingyan
    CANCER RESEARCH, 2023, 83 (05)
12345